Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP. According to reports from PTI, the approval covers multiple dosage strengths ranging from 25 mcg to 300 mcg, providing comprehensive coverage across the therapeutic spectrum. The company announced this development in a regulatory filing on Friday, marking a significant milestone for its US market expansion. As reported by The Economic Times, this medication is used as a replacement therapy for hypothyroidism, making it a crucial treatment option for patients seeking affordable treatment alternatives.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Synthroid Tablets, manufactured by AbbVie, Inc. (AbbVie). As reported by PTI, this equivalence ensures that the generic version will have the same therapeutic effect as the branded medication, providing patients with an affordable alternative to the reference drug. The approved strengths include 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, matching the reference product specifications exactly. According to The Economic Times, this development is significant for patients seeking affordable treatment options in the US market.
According to PTI, Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. The medication is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. This broad therapeutic scope positions the drug as a versatile treatment option for various thyroid-related conditions, making it a crucial medication for patients requiring thyroid hormone replacement therapy.
The USFDA approval provides Alembic Pharmaceuticals with regulatory clearance to market this generic version of Levothyroxine Sodium Tablets in the United States. As reported by PTI, citing IQVIA data, Levothyroxine sodium tablets have an estimated market size of USD 1,869 million for 12 months ended March 2026. This substantial market opportunity positions the company to capitalize on the significant demand for this thyroid medication in the US pharmaceutical market, particularly strengthening its position in the thyroid medication segment. According to The Economic Times, the market for these tablets is substantial, providing substantial revenue potential for the company in the US generics market.
